Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
19 hedge funds and large institutions have $34.6M invested in Iterum Therapeutics in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 1 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.06% less ownership
Funds ownership: 2.82% → 2.76% (-0.06%)
5% less funds holding
Funds holding: 20 → 19 (-1)
17% less capital invested
Capital invested by funds: $41.9M → $34.6M (-$7.25M)
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$60.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$17.4K |
| 3 |
New York State Common Retirement Fund
Albany,
New York
|
+$13.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$686K |
| 2 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$31.8K |
| 3 |
Millennium Management
New York
|
-$22.2K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$20.2K |
| 5 |
NA
Neuburgh Advisers
Los Angeles,
California
|
-$10.8K |
ITRM Hedge Fund Activity: Q3 2019 in Review
19 of the 4,511 institutional investors tracked by Wall St. Rank reported a position in Iterum Therapeutics (ITRM) for Q3 2019, worth a combined $34.6M — down 17% from $41.9M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ITRM and 0 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 3 added.
The largest buyer was Granahan Investment Management, adding an estimated $60.8K. The largest seller was Franklin Resources, cutting an estimated $686K.
- 19 institutional investors held Iterum Therapeutics (ITRM) as of Q3 2019, down from 20 in Q2 2019.
- Funds reported $34.6M of Iterum Therapeutics stock for Q3 2019, down 17% quarter-over-quarter.
- 0 funds opened new Iterum Therapeutics positions in Q3 2019 and 1 closed out, a net change of -1 holder.
- The largest Iterum Therapeutics buyer in Q3 2019 was Granahan Investment Management, an estimated $60.8K added.
- The largest Iterum Therapeutics seller in Q3 2019 was Franklin Resources, an estimated $686K sold.
Based on aggregated 13F filings for Q3 2019.